Astrana Health (ASTH) Cost of Revenue (2010 - 2026)

Astrana Health has reported Cost of Revenue for 17 years, with the latest figure at $859.4 million in Q1 2026.

• Quarterly Cost of Revenue rose 56.51% year-over-year to $859.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.2 billion (up 58.97% YoY) and the FY2025 annual result came in at $2.8 billion, up 61.09% from the prior year.
• Cost of Revenue steadied at $859.4 million in Q1 2026 per ASTH's latest filing, from $855.5 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $859.4 million in Q1 2026 and troughed at $220.7 million in Q1 2022.
• A 5-year average of $445.8 million and a median of $330.4 million in 2024 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2024 and 2025: Cost of Revenue advanced 14.17% in 2024, then soared 111.95% in 2025.
• Over 5 years, Cost of Revenue stood at $253.1 million in 2022, then rose by 24.07% to $314.1 million in 2023, then jumped by 95.74% to $614.7 million in 2024, then surged by 39.16% to $855.5 million in 2025, then grew by 0.45% to $859.4 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $859.4 million, $855.5 million, and $858.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.